Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...
The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...
Alphabet created Isomorphic Labs in 2021, spinning it out from DeepMind, the AI startup it acquired in 2014. DeepMind’s ...
Lilly and Novartis have collectively pledged almost $3 billion to their partnerships with Isomorphic signed last year, which ...
It will receive follow-on capital from existing backer Alphabet. The London-based company’s goal is an ambitious one – to “solve all disease,” according to the Isomorphic Labs site.